nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—UGT2B7—Epirubicin—ovarian cancer	0.224	0.852	CbGbCtD
Etodolac—CYP2C9—Paclitaxel—ovarian cancer	0.039	0.148	CbGbCtD
Etodolac—PTGS2—ovarian follicle—ovarian cancer	0.00892	0.208	CbGeAlD
Etodolac—PTGS1—oviduct—ovarian cancer	0.0041	0.0956	CbGeAlD
Etodolac—RXRA—female reproductive system—ovarian cancer	0.00345	0.0805	CbGeAlD
Etodolac—RXRA—female gonad—ovarian cancer	0.00314	0.0733	CbGeAlD
Etodolac—UGT2B7—female reproductive system—ovarian cancer	0.00234	0.0546	CbGeAlD
Etodolac—UGT2B7—testis—ovarian cancer	0.00189	0.0441	CbGeAlD
Etodolac—PTGS2—myometrium—ovarian cancer	0.00125	0.0292	CbGeAlD
Etodolac—PTGS2—embryo—ovarian cancer	0.00121	0.0281	CbGeAlD
Etodolac—ALB—testis—ovarian cancer	0.00108	0.0252	CbGeAlD
Etodolac—PTGS1—epithelium—ovarian cancer	0.00103	0.024	CbGeAlD
Etodolac—PTGS1—uterine cervix—ovarian cancer	0.00102	0.0238	CbGeAlD
Etodolac—PTGS2—epithelium—ovarian cancer	0.000984	0.0229	CbGeAlD
Etodolac—PTGS2—uterine cervix—ovarian cancer	0.000976	0.0227	CbGeAlD
Etodolac—PTGS1—endometrium—ovarian cancer	0.000923	0.0215	CbGeAlD
Etodolac—PTGS2—endometrium—ovarian cancer	0.000882	0.0206	CbGeAlD
Etodolac—PTGS1—uterus—ovarian cancer	0.000851	0.0198	CbGeAlD
Etodolac—CYP2C9—female reproductive system—ovarian cancer	0.000838	0.0195	CbGeAlD
Etodolac—PTGS2—uterus—ovarian cancer	0.000813	0.019	CbGeAlD
Etodolac—ALB—lymph node—ovarian cancer	0.000785	0.0183	CbGeAlD
Etodolac—PTGS1—female reproductive system—ovarian cancer	0.000765	0.0178	CbGeAlD
Etodolac—PTGS2—female reproductive system—ovarian cancer	0.000731	0.017	CbGeAlD
Etodolac—PTGS1—female gonad—ovarian cancer	0.000696	0.0162	CbGeAlD
Etodolac—PTGS1—vagina—ovarian cancer	0.000692	0.0161	CbGeAlD
Etodolac—PTGS2—bone marrow—ovarian cancer	0.00069	0.0161	CbGeAlD
Etodolac—PTGS2—female gonad—ovarian cancer	0.000665	0.0155	CbGeAlD
Etodolac—PTGS2—vagina—ovarian cancer	0.000661	0.0154	CbGeAlD
Etodolac—PTGS1—testis—ovarian cancer	0.000617	0.0144	CbGeAlD
Etodolac—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00049	0.000942	CcSEcCtD
Etodolac—Bronchitis—Epirubicin—ovarian cancer	0.000488	0.00094	CcSEcCtD
Etodolac—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000488	0.00094	CcSEcCtD
Etodolac—Anaemia—Docetaxel—ovarian cancer	0.000485	0.000933	CcSEcCtD
Etodolac—Pancytopenia—Epirubicin—ovarian cancer	0.000482	0.000928	CcSEcCtD
Etodolac—Anorexia—Paclitaxel—ovarian cancer	0.000481	0.000927	CcSEcCtD
Etodolac—Gastritis—Doxorubicin—ovarian cancer	0.000481	0.000926	CcSEcCtD
Etodolac—Vomiting—Vinorelbine—ovarian cancer	0.000477	0.000919	CcSEcCtD
Etodolac—Dysuria—Epirubicin—ovarian cancer	0.000475	0.000914	CcSEcCtD
Etodolac—Neutropenia—Epirubicin—ovarian cancer	0.000475	0.000914	CcSEcCtD
Etodolac—Rash—Vinorelbine—ovarian cancer	0.000473	0.000912	CcSEcCtD
Etodolac—Dermatitis—Vinorelbine—ovarian cancer	0.000473	0.000911	CcSEcCtD
Etodolac—Abdominal distension—Doxorubicin—ovarian cancer	0.000473	0.000911	CcSEcCtD
Etodolac—Hypotension—Paclitaxel—ovarian cancer	0.000472	0.000909	CcSEcCtD
Etodolac—Headache—Vinorelbine—ovarian cancer	0.00047	0.000906	CcSEcCtD
Etodolac—Syncope—Docetaxel—ovarian cancer	0.00047	0.000906	CcSEcCtD
Etodolac—Asthma—Doxorubicin—ovarian cancer	0.00047	0.000905	CcSEcCtD
Etodolac—Leukopenia—Docetaxel—ovarian cancer	0.00047	0.000904	CcSEcCtD
Etodolac—Pollakiuria—Epirubicin—ovarian cancer	0.000469	0.000903	CcSEcCtD
Etodolac—Eosinophilia—Doxorubicin—ovarian cancer	0.000465	0.000896	CcSEcCtD
Etodolac—Palpitations—Docetaxel—ovarian cancer	0.000464	0.000892	CcSEcCtD
Etodolac—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000463	0.000892	CcSEcCtD
Etodolac—Loss of consciousness—Docetaxel—ovarian cancer	0.000461	0.000888	CcSEcCtD
Etodolac—Pancreatitis—Doxorubicin—ovarian cancer	0.000461	0.000887	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00046	0.000886	CcSEcCtD
Etodolac—Hyperglycaemia—Epirubicin—ovarian cancer	0.000458	0.000882	CcSEcCtD
Etodolac—Insomnia—Paclitaxel—ovarian cancer	0.000457	0.000879	CcSEcCtD
Etodolac—Pneumonia—Epirubicin—ovarian cancer	0.000455	0.000877	CcSEcCtD
Etodolac—Convulsion—Docetaxel—ovarian cancer	0.000454	0.000875	CcSEcCtD
Etodolac—Paraesthesia—Paclitaxel—ovarian cancer	0.000454	0.000873	CcSEcCtD
Etodolac—Hypertension—Docetaxel—ovarian cancer	0.000453	0.000872	CcSEcCtD
Etodolac—Bronchitis—Doxorubicin—ovarian cancer	0.000452	0.00087	CcSEcCtD
Etodolac—Dyspnoea—Paclitaxel—ovarian cancer	0.00045	0.000867	CcSEcCtD
Etodolac—Somnolence—Paclitaxel—ovarian cancer	0.000449	0.000864	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000449	0.000864	CcSEcCtD
Etodolac—PTGS1—lymph node—ovarian cancer	0.000447	0.0104	CbGeAlD
Etodolac—Arthralgia—Docetaxel—ovarian cancer	0.000447	0.00086	CcSEcCtD
Etodolac—Myalgia—Docetaxel—ovarian cancer	0.000447	0.00086	CcSEcCtD
Etodolac—Pancytopenia—Doxorubicin—ovarian cancer	0.000446	0.000859	CcSEcCtD
Etodolac—Nausea—Vinorelbine—ovarian cancer	0.000446	0.000859	CcSEcCtD
Etodolac—Renal failure—Epirubicin—ovarian cancer	0.000445	0.000857	CcSEcCtD
Etodolac—Dyspepsia—Paclitaxel—ovarian cancer	0.000445	0.000856	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—ovarian cancer	0.000441	0.00085	CcSEcCtD
Etodolac—Jaundice—Epirubicin—ovarian cancer	0.000441	0.00085	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—ovarian cancer	0.00044	0.000847	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—ovarian cancer	0.000439	0.000846	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—ovarian cancer	0.000439	0.000846	CcSEcCtD
Etodolac—Decreased appetite—Paclitaxel—ovarian cancer	0.000439	0.000845	CcSEcCtD
Etodolac—Dry mouth—Docetaxel—ovarian cancer	0.000437	0.000841	CcSEcCtD
Etodolac—Fatigue—Paclitaxel—ovarian cancer	0.000435	0.000838	CcSEcCtD
Etodolac—Sweating—Epirubicin—ovarian cancer	0.000434	0.000836	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—ovarian cancer	0.000434	0.000836	CcSEcCtD
Etodolac—Constipation—Paclitaxel—ovarian cancer	0.000432	0.000832	CcSEcCtD
Etodolac—Pain—Paclitaxel—ovarian cancer	0.000432	0.000832	CcSEcCtD
Etodolac—Haematuria—Epirubicin—ovarian cancer	0.000432	0.000831	CcSEcCtD
Etodolac—Confusional state—Docetaxel—ovarian cancer	0.000432	0.000831	CcSEcCtD
Etodolac—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000429	0.000826	CcSEcCtD
Etodolac—Oedema—Docetaxel—ovarian cancer	0.000428	0.000824	CcSEcCtD
Etodolac—Anaphylactic shock—Docetaxel—ovarian cancer	0.000428	0.000824	CcSEcCtD
Etodolac—PTGS2—lymph node—ovarian cancer	0.000428	0.00997	CbGeAlD
Etodolac—Infection—Docetaxel—ovarian cancer	0.000425	0.000819	CcSEcCtD
Etodolac—Sinusitis—Epirubicin—ovarian cancer	0.000425	0.000818	CcSEcCtD
Etodolac—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000424	0.000816	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—ovarian cancer	0.000423	0.000813	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—ovarian cancer	0.000421	0.000811	CcSEcCtD
Etodolac—Shock—Docetaxel—ovarian cancer	0.000421	0.000811	CcSEcCtD
Etodolac—Thrombocytopenia—Docetaxel—ovarian cancer	0.000419	0.000807	CcSEcCtD
Etodolac—Tachycardia—Docetaxel—ovarian cancer	0.000418	0.000804	CcSEcCtD
Etodolac—Feeling abnormal—Paclitaxel—ovarian cancer	0.000416	0.000801	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000415	0.0008	CcSEcCtD
Etodolac—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000413	0.000795	CcSEcCtD
Etodolac—Renal failure—Doxorubicin—ovarian cancer	0.000412	0.000793	CcSEcCtD
Etodolac—Haemoglobin—Epirubicin—ovarian cancer	0.000408	0.000786	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—ovarian cancer	0.000408	0.000786	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—ovarian cancer	0.000408	0.000786	CcSEcCtD
Etodolac—Anorexia—Docetaxel—ovarian cancer	0.000408	0.000786	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—ovarian cancer	0.000407	0.000784	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—ovarian cancer	0.000407	0.000784	CcSEcCtD
Etodolac—Haemorrhage—Epirubicin—ovarian cancer	0.000406	0.000782	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—ovarian cancer	0.000406	0.000782	CcSEcCtD
Etodolac—Pharyngitis—Epirubicin—ovarian cancer	0.000403	0.000777	CcSEcCtD
Etodolac—Sweating—Doxorubicin—ovarian cancer	0.000402	0.000773	CcSEcCtD
Etodolac—Urticaria—Paclitaxel—ovarian cancer	0.000401	0.000772	CcSEcCtD
Etodolac—Hypotension—Docetaxel—ovarian cancer	0.0004	0.00077	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—ovarian cancer	0.000399	0.000769	CcSEcCtD
Etodolac—Abdominal pain—Paclitaxel—ovarian cancer	0.000399	0.000769	CcSEcCtD
Etodolac—Body temperature increased—Paclitaxel—ovarian cancer	0.000399	0.000769	CcSEcCtD
Etodolac—Sinusitis—Doxorubicin—ovarian cancer	0.000393	0.000757	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—ovarian cancer	0.000392	0.000754	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—ovarian cancer	0.000391	0.000753	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00039	0.000751	CcSEcCtD
Etodolac—Insomnia—Docetaxel—ovarian cancer	0.000387	0.000745	CcSEcCtD
Etodolac—Paraesthesia—Docetaxel—ovarian cancer	0.000384	0.00074	CcSEcCtD
Etodolac—Erythema multiforme—Epirubicin—ovarian cancer	0.000384	0.00074	CcSEcCtD
Etodolac—Dyspnoea—Docetaxel—ovarian cancer	0.000382	0.000735	CcSEcCtD
Etodolac—Somnolence—Docetaxel—ovarian cancer	0.000381	0.000733	CcSEcCtD
Etodolac—Tinnitus—Epirubicin—ovarian cancer	0.000379	0.00073	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—ovarian cancer	0.000378	0.000728	CcSEcCtD
Etodolac—Flushing—Epirubicin—ovarian cancer	0.000377	0.000726	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—ovarian cancer	0.000377	0.000726	CcSEcCtD
Etodolac—Dyspepsia—Docetaxel—ovarian cancer	0.000377	0.000726	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—ovarian cancer	0.000376	0.000724	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—ovarian cancer	0.000376	0.000724	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—ovarian cancer	0.000373	0.000719	CcSEcCtD
Etodolac—Decreased appetite—Docetaxel—ovarian cancer	0.000372	0.000716	CcSEcCtD
Etodolac—Hypersensitivity—Paclitaxel—ovarian cancer	0.000372	0.000716	CcSEcCtD
Etodolac—Fatigue—Docetaxel—ovarian cancer	0.000369	0.000711	CcSEcCtD
Etodolac—Pain—Docetaxel—ovarian cancer	0.000366	0.000705	CcSEcCtD
Etodolac—Constipation—Docetaxel—ovarian cancer	0.000366	0.000705	CcSEcCtD
Etodolac—Chills—Epirubicin—ovarian cancer	0.000365	0.000702	CcSEcCtD
Etodolac—Arrhythmia—Epirubicin—ovarian cancer	0.000363	0.000699	CcSEcCtD
Etodolac—Visual impairment—Doxorubicin—ovarian cancer	0.000362	0.000698	CcSEcCtD
Etodolac—Asthenia—Paclitaxel—ovarian cancer	0.000362	0.000698	CcSEcCtD
Etodolac—Alopecia—Epirubicin—ovarian cancer	0.000359	0.000691	CcSEcCtD
Etodolac—Pruritus—Paclitaxel—ovarian cancer	0.000357	0.000688	CcSEcCtD
Etodolac—Erythema multiforme—Doxorubicin—ovarian cancer	0.000356	0.000685	CcSEcCtD
Etodolac—Feeling abnormal—Docetaxel—ovarian cancer	0.000353	0.000679	CcSEcCtD
Etodolac—Tinnitus—Doxorubicin—ovarian cancer	0.000351	0.000675	CcSEcCtD
Etodolac—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00035	0.000674	CcSEcCtD
Etodolac—Flushing—Doxorubicin—ovarian cancer	0.000349	0.000672	CcSEcCtD
Etodolac—Flatulence—Epirubicin—ovarian cancer	0.000349	0.000671	CcSEcCtD
Etodolac—Tension—Epirubicin—ovarian cancer	0.000347	0.000668	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—ovarian cancer	0.000346	0.000667	CcSEcCtD
Etodolac—Diarrhoea—Paclitaxel—ovarian cancer	0.000346	0.000665	CcSEcCtD
Etodolac—Nervousness—Epirubicin—ovarian cancer	0.000344	0.000662	CcSEcCtD
Etodolac—Abdominal pain—Docetaxel—ovarian cancer	0.000338	0.000652	CcSEcCtD
Etodolac—Body temperature increased—Docetaxel—ovarian cancer	0.000338	0.000652	CcSEcCtD
Etodolac—Chills—Doxorubicin—ovarian cancer	0.000337	0.00065	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—ovarian cancer	0.000336	0.000647	CcSEcCtD
Etodolac—Dizziness—Paclitaxel—ovarian cancer	0.000334	0.000643	CcSEcCtD
Etodolac—Vision blurred—Epirubicin—ovarian cancer	0.000333	0.000642	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—ovarian cancer	0.000332	0.00064	CcSEcCtD
Etodolac—Ill-defined disorder—Epirubicin—ovarian cancer	0.000328	0.000632	CcSEcCtD
Etodolac—Anaemia—Epirubicin—ovarian cancer	0.000327	0.00063	CcSEcCtD
Etodolac—Flatulence—Doxorubicin—ovarian cancer	0.000323	0.000621	CcSEcCtD
Etodolac—Tension—Doxorubicin—ovarian cancer	0.000321	0.000618	CcSEcCtD
Etodolac—Vomiting—Paclitaxel—ovarian cancer	0.000321	0.000618	CcSEcCtD
Etodolac—Dysgeusia—Doxorubicin—ovarian cancer	0.000321	0.000617	CcSEcCtD
Etodolac—Malaise—Epirubicin—ovarian cancer	0.000319	0.000614	CcSEcCtD
Etodolac—Rash—Paclitaxel—ovarian cancer	0.000318	0.000613	CcSEcCtD
Etodolac—Dermatitis—Paclitaxel—ovarian cancer	0.000318	0.000613	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—ovarian cancer	0.000318	0.000612	CcSEcCtD
Etodolac—Vertigo—Epirubicin—ovarian cancer	0.000318	0.000612	CcSEcCtD
Etodolac—Syncope—Epirubicin—ovarian cancer	0.000317	0.000611	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—ovarian cancer	0.000317	0.00061	CcSEcCtD
Etodolac—Headache—Paclitaxel—ovarian cancer	0.000316	0.000609	CcSEcCtD
Etodolac—Hypersensitivity—Docetaxel—ovarian cancer	0.000315	0.000607	CcSEcCtD
Etodolac—Palpitations—Epirubicin—ovarian cancer	0.000313	0.000602	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—ovarian cancer	0.000311	0.000599	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—ovarian cancer	0.000309	0.000594	CcSEcCtD
Etodolac—Asthenia—Docetaxel—ovarian cancer	0.000307	0.000591	CcSEcCtD
Etodolac—Convulsion—Epirubicin—ovarian cancer	0.000307	0.00059	CcSEcCtD
Etodolac—Hypertension—Epirubicin—ovarian cancer	0.000305	0.000588	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000304	0.000585	CcSEcCtD
Etodolac—Pruritus—Docetaxel—ovarian cancer	0.000303	0.000583	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—ovarian cancer	0.000303	0.000583	CcSEcCtD
Etodolac—Myalgia—Epirubicin—ovarian cancer	0.000301	0.00058	CcSEcCtD
Etodolac—Arthralgia—Epirubicin—ovarian cancer	0.000301	0.00058	CcSEcCtD
Etodolac—Anxiety—Epirubicin—ovarian cancer	0.0003	0.000578	CcSEcCtD
Etodolac—Nausea—Paclitaxel—ovarian cancer	0.0003	0.000578	CcSEcCtD
Etodolac—Discomfort—Epirubicin—ovarian cancer	0.000298	0.000573	CcSEcCtD
Etodolac—Malaise—Doxorubicin—ovarian cancer	0.000295	0.000568	CcSEcCtD
Etodolac—Dry mouth—Epirubicin—ovarian cancer	0.000295	0.000567	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—ovarian cancer	0.000294	0.000566	CcSEcCtD
Etodolac—Syncope—Doxorubicin—ovarian cancer	0.000294	0.000565	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—ovarian cancer	0.000293	0.000564	CcSEcCtD
Etodolac—Diarrhoea—Docetaxel—ovarian cancer	0.000293	0.000564	CcSEcCtD
Etodolac—Confusional state—Epirubicin—ovarian cancer	0.000291	0.000561	CcSEcCtD
Etodolac—Palpitations—Doxorubicin—ovarian cancer	0.000289	0.000557	CcSEcCtD
Etodolac—Oedema—Epirubicin—ovarian cancer	0.000289	0.000556	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—ovarian cancer	0.000289	0.000556	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—ovarian cancer	0.000288	0.000554	CcSEcCtD
Etodolac—Infection—Epirubicin—ovarian cancer	0.000287	0.000552	CcSEcCtD
Etodolac—Shock—Epirubicin—ovarian cancer	0.000284	0.000547	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—ovarian cancer	0.000284	0.000546	CcSEcCtD
Etodolac—Dizziness—Docetaxel—ovarian cancer	0.000283	0.000545	CcSEcCtD
Etodolac—Thrombocytopenia—Epirubicin—ovarian cancer	0.000283	0.000544	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—ovarian cancer	0.000283	0.000544	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—ovarian cancer	0.000282	0.000543	CcSEcCtD
Etodolac—Hyperhidrosis—Epirubicin—ovarian cancer	0.000279	0.000537	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—ovarian cancer	0.000279	0.000537	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—ovarian cancer	0.000279	0.000537	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—ovarian cancer	0.000278	0.000535	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—ovarian cancer	0.000275	0.00053	CcSEcCtD
Etodolac—Anorexia—Epirubicin—ovarian cancer	0.000275	0.00053	CcSEcCtD
Etodolac—Dry mouth—Doxorubicin—ovarian cancer	0.000273	0.000525	CcSEcCtD
Etodolac—Vomiting—Docetaxel—ovarian cancer	0.000272	0.000524	CcSEcCtD
Etodolac—Rash—Docetaxel—ovarian cancer	0.00027	0.00052	CcSEcCtD
Etodolac—Hypotension—Epirubicin—ovarian cancer	0.00027	0.000519	CcSEcCtD
Etodolac—Dermatitis—Docetaxel—ovarian cancer	0.00027	0.000519	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—ovarian cancer	0.000269	0.000519	CcSEcCtD
Etodolac—Headache—Docetaxel—ovarian cancer	0.000268	0.000516	CcSEcCtD
Etodolac—Oedema—Doxorubicin—ovarian cancer	0.000267	0.000514	CcSEcCtD
Etodolac—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000267	0.000514	CcSEcCtD
Etodolac—Infection—Doxorubicin—ovarian cancer	0.000265	0.000511	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000263	0.000506	CcSEcCtD
Etodolac—Shock—Doxorubicin—ovarian cancer	0.000263	0.000506	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000262	0.000504	CcSEcCtD
Etodolac—Insomnia—Epirubicin—ovarian cancer	0.000261	0.000503	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—ovarian cancer	0.000261	0.000502	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—ovarian cancer	0.000259	0.000499	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000258	0.000497	CcSEcCtD
Etodolac—Dyspnoea—Epirubicin—ovarian cancer	0.000257	0.000496	CcSEcCtD
Etodolac—Somnolence—Epirubicin—ovarian cancer	0.000257	0.000494	CcSEcCtD
Etodolac—Anorexia—Doxorubicin—ovarian cancer	0.000255	0.00049	CcSEcCtD
Etodolac—Nausea—Docetaxel—ovarian cancer	0.000254	0.00049	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—ovarian cancer	0.000254	0.000489	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—ovarian cancer	0.000251	0.000483	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—ovarian cancer	0.00025	0.000481	CcSEcCtD
Etodolac—Fatigue—Epirubicin—ovarian cancer	0.000249	0.000479	CcSEcCtD
Etodolac—Pain—Epirubicin—ovarian cancer	0.000247	0.000475	CcSEcCtD
Etodolac—Constipation—Epirubicin—ovarian cancer	0.000247	0.000475	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000243	0.000469	CcSEcCtD
Etodolac—Insomnia—Doxorubicin—ovarian cancer	0.000242	0.000465	CcSEcCtD
Etodolac—Paraesthesia—Doxorubicin—ovarian cancer	0.00024	0.000462	CcSEcCtD
Etodolac—Dyspnoea—Doxorubicin—ovarian cancer	0.000238	0.000459	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—ovarian cancer	0.000238	0.000458	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—ovarian cancer	0.000238	0.000457	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000236	0.000455	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—ovarian cancer	0.000235	0.000453	CcSEcCtD
Etodolac—Decreased appetite—Doxorubicin—ovarian cancer	0.000232	0.000447	CcSEcCtD
Etodolac—Fatigue—Doxorubicin—ovarian cancer	0.00023	0.000443	CcSEcCtD
Etodolac—Urticaria—Epirubicin—ovarian cancer	0.000229	0.000442	CcSEcCtD
Etodolac—Constipation—Doxorubicin—ovarian cancer	0.000228	0.00044	CcSEcCtD
Etodolac—Pain—Doxorubicin—ovarian cancer	0.000228	0.00044	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—ovarian cancer	0.000228	0.000439	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—ovarian cancer	0.000228	0.000439	CcSEcCtD
Etodolac—Feeling abnormal—Doxorubicin—ovarian cancer	0.00022	0.000424	CcSEcCtD
Etodolac—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000218	0.000421	CcSEcCtD
Etodolac—Hypersensitivity—Epirubicin—ovarian cancer	0.000213	0.00041	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—ovarian cancer	0.000212	0.000409	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—ovarian cancer	0.000211	0.000407	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—ovarian cancer	0.000211	0.000407	CcSEcCtD
Etodolac—Asthenia—Epirubicin—ovarian cancer	0.000207	0.000399	CcSEcCtD
Etodolac—Pruritus—Epirubicin—ovarian cancer	0.000204	0.000393	CcSEcCtD
Etodolac—Diarrhoea—Epirubicin—ovarian cancer	0.000198	0.00038	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—ovarian cancer	0.000197	0.000379	CcSEcCtD
Etodolac—Asthenia—Doxorubicin—ovarian cancer	0.000192	0.000369	CcSEcCtD
Etodolac—Dizziness—Epirubicin—ovarian cancer	0.000191	0.000368	CcSEcCtD
Etodolac—Pruritus—Doxorubicin—ovarian cancer	0.000189	0.000364	CcSEcCtD
Etodolac—Vomiting—Epirubicin—ovarian cancer	0.000184	0.000353	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—ovarian cancer	0.000183	0.000352	CcSEcCtD
Etodolac—Rash—Epirubicin—ovarian cancer	0.000182	0.000351	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—ovarian cancer	0.000182	0.00035	CcSEcCtD
Etodolac—Headache—Epirubicin—ovarian cancer	0.000181	0.000348	CcSEcCtD
Etodolac—Dizziness—Doxorubicin—ovarian cancer	0.000177	0.00034	CcSEcCtD
Etodolac—Nausea—Epirubicin—ovarian cancer	0.000172	0.00033	CcSEcCtD
Etodolac—Vomiting—Doxorubicin—ovarian cancer	0.00017	0.000327	CcSEcCtD
Etodolac—Rash—Doxorubicin—ovarian cancer	0.000168	0.000324	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—ovarian cancer	0.000168	0.000324	CcSEcCtD
Etodolac—Headache—Doxorubicin—ovarian cancer	0.000167	0.000322	CcSEcCtD
Etodolac—Nausea—Doxorubicin—ovarian cancer	0.000159	0.000306	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	8.82e-05	0.000504	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	8.79e-05	0.000503	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	8.62e-05	0.000493	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	8.6e-05	0.000492	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—FASN—ovarian cancer	8.49e-05	0.000486	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—YAP1—ovarian cancer	8.47e-05	0.000484	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.45e-05	0.000483	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.38e-05	0.000479	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—ERBB2—ovarian cancer	8.36e-05	0.000478	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—SLC5A5—ovarian cancer	8.35e-05	0.000478	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPP2R1A—ovarian cancer	8.23e-05	0.000471	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	8.22e-05	0.00047	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—BRIP1—ovarian cancer	8.17e-05	0.000467	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPP1CC—ovarian cancer	8.17e-05	0.000467	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	8.15e-05	0.000466	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.11e-05	0.000464	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	8.08e-05	0.000462	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPP2R1A—ovarian cancer	8.07e-05	0.000461	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—SLC2A1—ovarian cancer	8.07e-05	0.000461	CbGpPWpGaD
Etodolac—RXRA—Metabolism—FASN—ovarian cancer	7.92e-05	0.000453	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	7.89e-05	0.000451	CbGpPWpGaD
Etodolac—RXRA—Metabolism—SLC5A5—ovarian cancer	7.79e-05	0.000446	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	7.76e-05	0.000444	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CYP1B1—ovarian cancer	7.73e-05	0.000442	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.59e-05	0.000434	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYTB—ovarian cancer	7.56e-05	0.000432	CbGpPWpGaD
Etodolac—RXRA—Metabolism—SLC2A1—ovarian cancer	7.53e-05	0.00043	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.5e-05	0.000429	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ABCB1—ovarian cancer	7.49e-05	0.000428	CbGpPWpGaD
Etodolac—PTGS2—Disease—HDAC6—ovarian cancer	7.39e-05	0.000423	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.39e-05	0.000423	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.37e-05	0.000421	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.36e-05	0.000421	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—TYMS—ovarian cancer	7.36e-05	0.000421	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.35e-05	0.00042	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.33e-05	0.000419	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—CTNNB1—ovarian cancer	7.32e-05	0.000418	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SOD1—ovarian cancer	7.23e-05	0.000414	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP1B1—ovarian cancer	7.21e-05	0.000413	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PPP2R1A—ovarian cancer	7.2e-05	0.000412	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MMP9—ovarian cancer	7.17e-05	0.00041	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	7.16e-05	0.00041	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	7.14e-05	0.000409	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	6.99e-05	0.0004	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	6.99e-05	0.0004	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—YAP1—ovarian cancer	6.9e-05	0.000395	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—FASN—ovarian cancer	6.9e-05	0.000395	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPP2R1A—ovarian cancer	6.86e-05	0.000392	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.83e-05	0.000391	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—SLC5A5—ovarian cancer	6.79e-05	0.000388	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.64e-05	0.00038	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPP1CC—ovarian cancer	6.61e-05	0.000378	CbGpPWpGaD
Etodolac—ALB—Metabolism—BRIP1—ovarian cancer	6.61e-05	0.000378	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	6.6e-05	0.000378	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	6.58e-05	0.000376	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—SLC2A1—ovarian cancer	6.56e-05	0.000375	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—VEGFA—ovarian cancer	6.44e-05	0.000368	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.42e-05	0.000367	CbGpPWpGaD
Etodolac—PTGS2—Disease—XIAP—ovarian cancer	6.41e-05	0.000366	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPP2R1A—ovarian cancer	6.4e-05	0.000366	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—STAT3—ovarian cancer	6.38e-05	0.000365	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ABCB1—ovarian cancer	6.37e-05	0.000364	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.37e-05	0.000364	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NRAS—ovarian cancer	6.36e-05	0.000364	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—ovarian cancer	6.29e-05	0.00036	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP1B1—ovarian cancer	6.29e-05	0.000359	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—TYMS—ovarian cancer	6.26e-05	0.000358	CbGpPWpGaD
Etodolac—PTGS2—Disease—SMARCA4—ovarian cancer	6.25e-05	0.000357	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYTB—ovarian cancer	6.19e-05	0.000354	CbGpPWpGaD
Etodolac—PTGS2—Disease—EREG—ovarian cancer	6.1e-05	0.000349	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MAPK3—ovarian cancer	6.09e-05	0.000348	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.06e-05	0.000347	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	6.05e-05	0.000346	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6e-05	0.000343	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.95e-05	0.00034	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ABCB1—ovarian cancer	5.94e-05	0.00034	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CAV1—ovarian cancer	5.93e-05	0.000339	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.87e-05	0.000336	CbGpPWpGaD
Etodolac—RXRA—Metabolism—TYMS—ovarian cancer	5.83e-05	0.000334	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—ESR1—ovarian cancer	5.83e-05	0.000333	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MAPK1—ovarian cancer	5.8e-05	0.000331	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EGFR—ovarian cancer	5.8e-05	0.000331	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.79e-05	0.000331	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—FASN—ovarian cancer	5.63e-05	0.000322	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	5.59e-05	0.00032	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	5.57e-05	0.000319	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.55e-05	0.000317	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—SLC5A5—ovarian cancer	5.53e-05	0.000316	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—YAP1—ovarian cancer	5.48e-05	0.000313	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—KRAS—ovarian cancer	5.47e-05	0.000313	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.42e-05	0.00031	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPP1CC—ovarian cancer	5.41e-05	0.000309	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—BRIP1—ovarian cancer	5.41e-05	0.000309	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CG—ovarian cancer	5.4e-05	0.000309	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—SLC2A1—ovarian cancer	5.34e-05	0.000306	CbGpPWpGaD
Etodolac—PTGS2—Disease—FASN—ovarian cancer	5.33e-05	0.000305	CbGpPWpGaD
Etodolac—PTGS2—Disease—PARP1—ovarian cancer	5.31e-05	0.000304	CbGpPWpGaD
Etodolac—ALB—Hemostasis—CAV1—ovarian cancer	5.29e-05	0.000302	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	5.29e-05	0.000302	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.23e-05	0.000299	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ABCB1—ovarian cancer	5.18e-05	0.000296	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP1B1—ovarian cancer	5.12e-05	0.000293	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—TYMS—ovarian cancer	5.08e-05	0.000291	CbGpPWpGaD
Etodolac—PTGS2—Disease—SLC2A1—ovarian cancer	5.07e-05	0.00029	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CAV1—ovarian cancer	5.04e-05	0.000288	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	5.03e-05	0.000288	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.95e-05	0.000283	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CG—ovarian cancer	4.82e-05	0.000276	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.82e-05	0.000275	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.77e-05	0.000273	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CD—ovarian cancer	4.75e-05	0.000271	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CAV1—ovarian cancer	4.7e-05	0.000269	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—ovarian cancer	4.65e-05	0.000266	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CG—ovarian cancer	4.59e-05	0.000263	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPP2R1A—ovarian cancer	4.54e-05	0.00026	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.52e-05	0.000259	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.49e-05	0.000257	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—FASN—ovarian cancer	4.47e-05	0.000255	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—IL6—ovarian cancer	4.45e-05	0.000255	CbGpPWpGaD
Etodolac—ALB—Metabolism—YAP1—ovarian cancer	4.43e-05	0.000253	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—SLC5A5—ovarian cancer	4.39e-05	0.000251	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.39e-05	0.000251	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	4.37e-05	0.00025	CbGpPWpGaD
Etodolac—PTGS2—Disease—PPP2R1A—ovarian cancer	4.31e-05	0.000246	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CG—ovarian cancer	4.28e-05	0.000245	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—SLC2A1—ovarian cancer	4.24e-05	0.000243	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CD—ovarian cancer	4.24e-05	0.000242	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ABCB1—ovarian cancer	4.22e-05	0.000241	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.15e-05	0.000238	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TYMS—ovarian cancer	4.14e-05	0.000237	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CB—ovarian cancer	4.14e-05	0.000237	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—AKT1—ovarian cancer	4.11e-05	0.000235	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CAV1—ovarian cancer	4.1e-05	0.000234	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP1B1—ovarian cancer	4.07e-05	0.000233	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CD—ovarian cancer	4.04e-05	0.000231	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.94e-05	0.000225	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.91e-05	0.000224	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.86e-05	0.000221	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CD—ovarian cancer	3.76e-05	0.000215	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CG—ovarian cancer	3.73e-05	0.000213	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CB—ovarian cancer	3.69e-05	0.000211	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—YAP1—ovarian cancer	3.63e-05	0.000207	CbGpPWpGaD
Etodolac—ALB—Metabolism—FASN—ovarian cancer	3.61e-05	0.000207	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPP2R1A—ovarian cancer	3.61e-05	0.000206	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.59e-05	0.000205	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.59e-05	0.000205	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTEN—ovarian cancer	3.58e-05	0.000204	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	3.57e-05	0.000204	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC5A5—ovarian cancer	3.55e-05	0.000203	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CB—ovarian cancer	3.52e-05	0.000201	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC2A1—ovarian cancer	3.43e-05	0.000196	CbGpPWpGaD
Etodolac—PTGS2—Disease—TERT—ovarian cancer	3.42e-05	0.000196	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IL2—ovarian cancer	3.39e-05	0.000194	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.36e-05	0.000192	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ABCB1—ovarian cancer	3.35e-05	0.000192	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CAV1—ovarian cancer	3.34e-05	0.000191	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP1B1—ovarian cancer	3.29e-05	0.000188	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TYMS—ovarian cancer	3.29e-05	0.000188	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CB—ovarian cancer	3.28e-05	0.000188	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CD—ovarian cancer	3.28e-05	0.000188	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.19e-05	0.000182	CbGpPWpGaD
Etodolac—PTGS2—Disease—CAV1—ovarian cancer	3.17e-05	0.000181	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.16e-05	0.00018	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MAPK3—ovarian cancer	3.12e-05	0.000178	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CG—ovarian cancer	3.04e-05	0.000174	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTEN—ovarian cancer	3.04e-05	0.000174	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—ovarian cancer	3.03e-05	0.000173	CbGpPWpGaD
Etodolac—PTGS2—Disease—IL6ST—ovarian cancer	3e-05	0.000172	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—FASN—ovarian cancer	2.96e-05	0.000169	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPP2R1A—ovarian cancer	2.92e-05	0.000167	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.91e-05	0.000166	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.9e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS2—Disease—APC—ovarian cancer	2.88e-05	0.000165	CbGpPWpGaD
Etodolac—ALB—Hemostasis—VEGFA—ovarian cancer	2.88e-05	0.000165	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CB—ovarian cancer	2.86e-05	0.000163	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NRAS—ovarian cancer	2.85e-05	0.000163	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTEN—ovarian cancer	2.84e-05	0.000162	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.81e-05	0.000161	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.75e-05	0.000157	CbGpPWpGaD
Etodolac—ALB—Hemostasis—MAPK3—ovarian cancer	2.73e-05	0.000156	CbGpPWpGaD
Etodolac—ALB—Metabolism—ABCB1—ovarian cancer	2.71e-05	0.000155	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.69e-05	0.000154	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CD—ovarian cancer	2.67e-05	0.000153	CbGpPWpGaD
Etodolac—ALB—Metabolism—TYMS—ovarian cancer	2.66e-05	0.000152	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CAV1—ovarian cancer	2.65e-05	0.000152	CbGpPWpGaD
Etodolac—ALB—Hemostasis—MAPK1—ovarian cancer	2.59e-05	0.000148	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CD—ovarian cancer	2.53e-05	0.000145	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.53e-05	0.000145	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CA—ovarian cancer	2.52e-05	0.000144	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTEN—ovarian cancer	2.47e-05	0.000141	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KRAS—ovarian cancer	2.45e-05	0.00014	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CG—ovarian cancer	2.41e-05	0.000138	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.39e-05	0.000137	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.38e-05	0.000136	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CB—ovarian cancer	2.33e-05	0.000133	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CA—ovarian cancer	2.25e-05	0.000129	CbGpPWpGaD
Etodolac—PTGS2—Disease—ERBB2—ovarian cancer	2.24e-05	0.000128	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.22e-05	0.000127	CbGpPWpGaD
Etodolac—PTGS2—Disease—MTOR—ovarian cancer	2.21e-05	0.000126	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CB—ovarian cancer	2.21e-05	0.000126	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TYMS—ovarian cancer	2.18e-05	0.000125	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—ovarian cancer	2.18e-05	0.000125	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CA—ovarian cancer	2.14e-05	0.000123	CbGpPWpGaD
Etodolac—ALB—Metabolism—CAV1—ovarian cancer	2.14e-05	0.000123	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CD—ovarian cancer	2.12e-05	0.000121	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—AKT1—ovarian cancer	2.1e-05	0.00012	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—ovarian cancer	2.08e-05	0.000119	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1B—ovarian cancer	2.07e-05	0.000119	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—AKT1—ovarian cancer	2.06e-05	0.000118	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.05e-05	0.000117	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTEN—ovarian cancer	2.01e-05	0.000115	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CA—ovarian cancer	2e-05	0.000114	CbGpPWpGaD
Etodolac—PTGS2—Disease—CTNNB1—ovarian cancer	1.96e-05	0.000112	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CG—ovarian cancer	1.95e-05	0.000112	CbGpPWpGaD
Etodolac—PTGS2—Disease—PTEN—ovarian cancer	1.91e-05	0.000109	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CB—ovarian cancer	1.85e-05	0.000106	CbGpPWpGaD
Etodolac—ALB—Hemostasis—AKT1—ovarian cancer	1.84e-05	0.000105	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CAV1—ovarian cancer	1.76e-05	0.0001	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—AKT1—ovarian cancer	1.75e-05	0.0001	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CA—ovarian cancer	1.74e-05	9.97e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CD—ovarian cancer	1.72e-05	9.82e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—STAT3—ovarian cancer	1.71e-05	9.76e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—NRAS—ovarian cancer	1.7e-05	9.74e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.68e-05	9.59e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—AKT1—ovarian cancer	1.63e-05	9.35e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MAPK3—ovarian cancer	1.63e-05	9.33e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.6e-05	9.14e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PTEN—ovarian cancer	1.6e-05	9.14e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—ovarian cancer	1.59e-05	9.07e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MAPK1—ovarian cancer	1.55e-05	8.88e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—EGFR—ovarian cancer	1.55e-05	8.87e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CB—ovarian cancer	1.5e-05	8.56e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—KRAS—ovarian cancer	1.47e-05	8.38e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—AKT1—ovarian cancer	1.42e-05	8.14e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CA—ovarian cancer	1.42e-05	8.12e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.41e-05	8.04e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CA—ovarian cancer	1.35e-05	7.7e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTEN—ovarian cancer	1.29e-05	7.4e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—ovarian cancer	1.25e-05	7.13e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.23e-05	7.01e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—IL6—ovarian cancer	1.19e-05	6.82e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—AKT1—ovarian cancer	1.16e-05	6.64e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CA—ovarian cancer	1.13e-05	6.45e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—AKT1—ovarian cancer	1.1e-05	6.29e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTEN—ovarian cancer	1.06e-05	6.05e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—AKT1—ovarian cancer	9.21e-06	5.27e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CA—ovarian cancer	9.12e-06	5.22e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CA—ovarian cancer	7.47e-06	4.27e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—AKT1—ovarian cancer	7.45e-06	4.26e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—AKT1—ovarian cancer	6.1e-06	3.49e-05	CbGpPWpGaD
